Regulatory March 24, 2021 Oasmia wins sole rights to record patents in its own name and is awarded full legal costs
Regulatory March 1, 2021 Oasmia acquires global development and commercialization rights for Cantrixil, a clinical stage, ovarian cancer program
Regulatory February 19, 2021 Year-end report[1] for the shortened[2] financial year May 1, 2020 – December 31, 2020
